drugset / Trial / NCT04606576

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04606576 ↗

Phase 3 Terminated 710 enrolled Oramed, Ltd. Integrium · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.

Timeline

Start
2020-12-15
Primary completion
2023-01-13
Completion
2023-01-13

Outcome

Outcome not reported

Stopped: “ORA-D-013-1 was terminated based on the primary results analyzed at the end of the treatment, week 26.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ORMD-0801 Protein / enzyme biologic 8 mg Oral